The global contraceptive drugs market size attained a value of USD 17.42 billion in 2022. The market is further expected to grow at a CAGR of 7.02% during the forecast period of 2023-2031 to attain a value of USD 32.08 billion by 2031. The growth of the market is driven by the increasing awareness and acceptance of contraceptive drugs.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
As governments are increasingly attempting to enhance the quality of life of their citizens, they are increasingly providing free and subsidised contraceptive drugs, thereby driving the growth of the market. Moreover, governments of low-and-middle-income companies are launching various favourable initiatives like advertisements to promote contraceptive drugs among their population.
For instance, in July 2019, the Health Ministry of India released about three commercials to promote oral contraceptives. In addition, various governments are selling contraceptive pills at pharmacy stores without doctor’s prescriptions, which is significantly contributing to the growth of the market.
The initiation of various family planning programmes and media campaigns to increase awareness regarding the importance and benefits of contraceptive drugs is augmenting the market growth. The redistribution of contraceptive services among health workers and pharmacy staff, among others, is increasing the accessibility of the underserved population of injectables and oral contractions. Hence, the increasing availability of diverse contraceptive drugs in developing countries is aiding the market growth. The development of new contraceptive technologies to boost the functionality and efficiency of contraceptive drugs is providing further impetus to the growth of the market.
Contraceptive drugs, variously known as birth control drugs, are medicines that prevent unwanted pregnancies by releasing hormones like oestrogen and progesterone. They thicken mucus around the cervix to prevent ovulation. Contraceptive drugs are convenient to use and lower the risk of various health-related issues like breast cancer and polycystic ovary syndrome (PCOS), among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major products of contraceptive drugs are:
The market can be broadly categorised on the basis of its age groups into:
Based on end-users, the market is divided into:
The EMR report looks into the regional markets of contraceptive drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The development of innovative contraceptive drugs to minimise the side-effects like nausea and vomiting is propelling the market growth. With the increasing attempts to boost the benefits of contraceptive drugs, new modes for their administration to enhance patient experience is surging, which is aiding the market growth. Furthermore, the increasing research activities to develop advanced contraceptive drugs is expected to propel the market growth. The rising acceptance of innovative contraceptive drugs like once-a-month pills to prevent ovulation or implantation is significantly contributing to the growth of the industry.
The increasing focus to provide innovative solutions for shared reproductive burden among both males and females is anticipated to drive the growth of the market. This is also leading to the initiation of various clinical trials of contraceptive drugs that stop sperm production to prevent unplanned pregnancies. As conventional contraceptive drugs result in side effects like nausea, vomiting, and mood swings, among others, long-acting reversible contraceptives are being developed, which is anticipated to bolster the industry growth. Moreover, increasing research activities to develop oestrogen-free drugs to lower failure rates as compared to oestrogen-based contraception is predicted to propel the market growth.
The report presents a detailed analysis of the following key players in the global contraceptive drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product Type||
|Breakup by Route of Administration||
|Breakup by Therapy Type||
|Breakup by Age Group||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Contraceptive Drugs Market Overview
3.1 Global Contraceptive Drugs Market Historical Value (2016-2022)
3.2 Global Contraceptive Drugs Market Forecast Value (2023-2031)
4 Global Contraceptive Drugs Market Landscape
4.1 Global Contraceptive Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Contraceptive Drugs Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Route of Administration
4.2.3 Analysis by Age Group
4.2.4 Analysis by Therapy Type
4.2.5 Analysis by Distribution Channel
5 Global Contraceptive Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Contraceptive Drugs Market Segmentation
6.1 Global Contraceptive Drugs Market by Product Type
6.1.1 Market Overview
6.1.2 Contraceptive Drugs
126.96.36.199 Contraceptive Pills
6.2 Global Contraceptive Drugs Market by Route of Administration
6.2.1 Market Overview
6.3 Global Contraceptive Drugs Market by Therapy Type
6.3.1 Market Overview
6.3.3 Combined Contraceptives
6.4 Global Contraceptive Drugs Market by Age Group
6.4.1 Market Overview
6.4.2 15-45 Years
6.4.3 Above 45 Years
6.5 Global Contraceptive Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.5 Online Channel
6.5.6 Public Channel
6.5.7 NGOs, Others
6.6 Global Contraceptive Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Contraceptive Drugs Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Contraceptive Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Contraceptive Drugs Market
9.1 Market Share by Country
10 Latin America Contraceptive Drugs Market
10.1 Market Share by Country
11 Middle East and Africa Contraceptive Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 Piramal Enterprises Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 Agile Therapeutics
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 Johnson & Johnson Services, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Abbive Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Merck & Co Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Teva Pharmaceuticals Industries Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Bayer AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 Helm AG.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Reckitt Benckiser Group PLC
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11 Viatris Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12 Amneal Pharmaceuticals LLC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 Bayer AG
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14 Allergan plc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.15 Agile Therapeutics
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
18 Global Contraceptive Drugs Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2022, the global contraceptive drugs market attained a value of nearly USD 17.41 billion.
The market is projected to grow at a CAGR of 7% between 2023 and 2031.
The market is estimated to witness a healthy growth in the forecast period of 2023-2031 to reach about USD 32 billion by 2031.
The market is being aided by the increasing availability of free and subsidised contraceptive drugs, the initiation of various family planning programmes and media campaigns, and the development of new contraceptive technologies.
The industry is expected to be augmented by the development of advanced contraceptive drugs, the rising acceptance of innovative contraceptive drugs, and the increasing clinical trials of contraceptive drugs for men.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major products of contraceptive drugs in the industry are topical contraceptives, oral contraceptive pills, and injectable contraceptives.
The significant age groups in the market are 15-24 years, 25-34 years, 35-44 years, and above 44 years.
The various end-users of contraceptive drugs are homecare, hospitals, and clinics.
The major players in the industry are Allergan plc, Johnson & Johnson, Bayer AG, Piramal Healthcare, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG, among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.